How China's Premium Healthcare Assets Break Through Global Markets in the Era of Industry-Finance Synergy: Full Agenda Unveiled for 2025 Changping Healthcare & Finance Innovation Forum

In 2025, the global pharmaceutical and healthcare industry is undergoing profound transformation and restructuring. From innovative drug development to breakthroughs in medical devices, and from the synthetic biology revolution to AI-driven drug discovery innovations, technological iterations and capital flows are weaving a new landscape for the healthcare sector. Although investment and financing activities in the pharmaceutical and healthcare fields have become more rational, hard-core sectors such as cell and gene therapy, interventional devices, and synthetic biology continue to demonstrate robust vitality. Industrial consolidation and global expansion have emerged as new trends. As high-quality Chinese pharmaceutical and healthcare assets go global, how can they overcome technical barriers and geopolitical constraints? How can “industry-finance synergy” be leveraged to resolve the challenges of cross-border cooperation?

As a premier innovation hub for the pharmaceutical and health industries in the capital, Changping District, Beijing, has gathered nearly 2,000 enterprises, incubated 112 companies founded by scientists, and approved 29 innovative medical devices, thereby establishing a full-chain ecosystem encompassing “R&D, translation, and industrialization.” Against this backdrop, the event is hosted by the People’s Government of Changping District, Beijing, and Beijing State-owned Capital Operation and Management Co., Ltd., and jointly organized by the Future Science City Management Committee (Life Science Park Management Committee), the Development and Reform Commission of Changping District, Beijing, the Changping Future Venture Capital Alliance, the Management Committee of Zhongguancun Science Park Changping Park, Beijing Changping Science and Technology Park Development Group Co., Ltd., Beijing Changke Jin Investment Co., Ltd., and Chongqing Artery Orange Technology Co., Ltd. (VCBeat).2025 Changping Pharmaceutical and Health Finance Investment Innovation Forum (CHIF), will open on July 7 at the Changping Oil Science and Technology Exchange Center, bringing together stakeholders from government, industry, academia, research, and investment sectors to jointly explore pathways for breaking through global development challenges in an era of industry-finance synergy.

★ Led by academicians, a top-tier think tank decodes the industry frontier.A top-tier think tank, led by academicians, will focus on the latest and most trending topics in industries such as molecular medicine and AI-driven drug discovery, offering in-depth insights and discussions. They will share cutting-edge research findings in molecular medicine and practical case studies of AI reshaping the drug R&D value chain, while analyzing the end-to-end pathway from laboratory breakthroughs to industrial implementation, decoding new breakthroughs and paradigms in technology translation and commercialization.

★ Focusing on Hard Tech, Directly Addressing Industrial Pain Points and Opportunities.Anchoring in hardcore sectors such as molecular medicine and AI-driven drug discovery, we explore the bidirectional empowerment between frontier technologies and the healthcare industry. Closely aligned with global industrial shifts, we delve into critical real-world issues, including strategies for autonomous controllability under the impact of U.S. tariffs and the logic behind the restructuring of the pharmaceutical outsourcing supply chain amid geopolitical conflicts. By leveraging technological innovation and capital intelligence to address industry pain points, we seize new growth opportunities amidst transformation.

★ Industry-finance synergy: In-depth dialogue on internationalization pathways.Exclusive Dual Roundtable High-End Dialogue: Bringing together elites from multinational pharmaceutical companies, international investment banks, and leading investment institutions to deconstruct the globalization pathways and exit strategy choices for high-quality assets in China’s healthcare sector. With an international perspective, we deeply analyze practical cases to distill actionable cross-border cooperation paradigms and capital operation models, providing forward-looking and practical solutions for industry-finance collaborative innovation.

★ Changping’s Momentum: Unleashing the Dividends of Regional Industrial Clusters.As a key component of the core area for Beijing’s International Science and Technology Innovation Center, Changping District will comprehensively showcase benchmark cases of the synergistic development of “pharmaceuticals and healthcare + financial capital.” On-site, exclusive channels will be opened to connect enterprises with scarce resources such as industrial park space carriers and direct investments from government-guided funds, providing full-cycle empowerment from technology research and development to commercial implementation.